Cardio Diagnostics Holdings, Inc. (CDIO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cardio Diagnostics Holdings, Inc. (CDIO) Healthcare & Pipeline Overview

Cardio Diagnostics Holdings, Inc. specializes in advanced clinical diagnostics for cardiovascular disease, utilizing epigenetic insights to enhance risk assessment and promote preventative care in a rapidly evolving healthcare landscape.

What Is the Investment Thesis for CDIO?

Cardio Diagnostics Holdings, Inc. presents a compelling case for growth driven by its innovative Epi+Gen CHD test, which addresses a critical need in cardiovascular disease diagnostics. The company operates in a market projected to grow significantly due to increasing awareness of cardiovascular health and the demand for personalized medicine. With a profit margin of -40152.5% and a gross margin of -471.4%, the company is currently in a development phase, necessitating close monitoring of its ability to secure partnerships and achieve regulatory milestones. The successful commercialization of its products could lead to substantial revenue streams, particularly as the healthcare sector increasingly prioritizes preventative care. However, ongoing competition from established diagnostics firms poses a risk that could impact market share and growth potential.

Based on FMP financials and quantitative analysis

CDIO Key Highlights

Market Cap of $5.86M indicates a nascent stage in the market.

• Profit Margin of -40152.5% reflects current operational challenges.
• Gross Margin of -471.4% indicates significant cost pressures in product development.
• Beta of 2.20 suggests higher volatility compared to the market.
• No dividend yield as the company reinvests in growth and development.

Who Are CDIO's Competitors?

CDIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDIO's Key Strengths?

Innovative product offerings targeting cardiovascular diagnostics.

• Expertise in epigenetic insights enhances diagnostic accuracy.
• Strong focus on personalized medicine aligns with market demand.

What Are CDIO's Weaknesses?

Current negative profit and gross margins indicate financial challenges.

• Limited operational scale with only 13 employees.
• Dependence on successful product development and regulatory approvals.

What Could Drive CDIO Stock Higher?

CDIO catalyst: Completion of regulatory approval processes for the Epi+Gen CHD test, which could enhance market entry.

• Development of strategic partnerships with healthcare providers to expand market reach and product validation.
• Continuous research and development efforts aimed at innovating new diagnostic tools and improving existing offerings.

What Are the Key Risks for CDIO?

Financial-distress signal — its Altman Z-Score of -0.20 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-78.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles may impact the timeline for product launches and market entry.
• Intense competition from established players in the diagnostics market could affect market share.
• Financial instability due to negative profit margins may limit operational capabilities and growth.

What Are the Growth Opportunities for CDIO?

• Growth opportunity 1: The global cardiovascular diagnostics market is expected to reach $3.7 billion by 2026, driven by rising incidences of cardiovascular diseases and a growing focus on early detection. Cardio Diagnostics, with its Epi+Gen CHD test, is positioned to capture a share of this expanding market by offering innovative solutions that leverage epigenetic insights.
• Growth opportunity 2: The increasing demand for personalized medicine presents a significant opportunity for Cardio Diagnostics. As healthcare shifts towards tailored treatment plans, the company's focus on risk stratification tools aligns with market needs. This trend is expected to grow, with personalized medicine projected to reach $2.4 trillion by 2028, providing a favorable environment for Cardio Diagnostics' offerings.
• Growth opportunity 3: Strategic partnerships with healthcare providers and research institutions could enhance Cardio Diagnostics' market reach and credibility. Collaborations that focus on clinical trials and product validation can accelerate the adoption of their diagnostic tools, positioning the company as a leader in cardiovascular diagnostics.
• Growth opportunity 4: Regulatory approvals for innovative diagnostic tests can significantly boost market entry and credibility. Cardio Diagnostics is actively pursuing necessary certifications and approvals, which could facilitate access to broader markets and enhance trust among healthcare professionals and patients alike.
• Growth opportunity 5: The rise of telemedicine and remote patient monitoring creates avenues for Cardio Diagnostics to integrate its diagnostic tools into digital health platforms. By leveraging technology, the company can expand its reach and provide accessible solutions for cardiovascular risk assessment, aligning with the trend towards digital healthcare.

What Are CDIO's Competitive Advantages?

• Unique epigenetic approach to cardiovascular diagnostics.
• Focus on personalized medicine aligns with market trends.
• Innovative product offerings that differentiate from competitors.
• Potential for strategic partnerships to enhance market presence.

What Does CDIO Do?

Founded in 2017 and headquartered in Chicago, Illinois, Cardio Diagnostics Holdings, Inc. is dedicated to developing advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. The company’s flagship product, Epi+Gen CHD, is a groundbreaking test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. By focusing on risk stratification, Cardio Diagnostics aims to improve early detection and personalized treatment plans, responding to the growing demand for preventative cardiovascular care. The company operates in a highly competitive market, where established players dominate, yet it strives to carve out a niche through innovative technology and strategic partnerships. With a small team of 13 employees, Cardio Diagnostics is positioned to rapidly adapt to the evolving landscape of healthcare diagnostics, emphasizing the importance of personalized medicine in improving patient outcomes. As the global focus on preventative healthcare intensifies, Cardio Diagnostics is well-placed to contribute significantly to the field of cardiovascular diagnostics, offering unique insights that could redefine patient care.

What Products and Services Does CDIO Offer?

• Develop advanced clinical diagnostic tools for cardiovascular disease.
• Leverage epigenetic insights to create innovative testing solutions.
• Offer the Epi+Gen CHD test to assess risk for coronary heart disease.
• Focus on risk stratification for improved patient outcomes.
• Aim to enhance early detection and personalized treatment plans.
• Engage in partnerships to expand market reach and product validation.

How Does CDIO Make Money?

• Generate revenue through the sale of diagnostic tests.
• Engage in partnerships with healthcare providers for product distribution.
• Focus on research and development to innovate new diagnostic solutions.
• Leverage grants and funding for product development and clinical trials.

What Industry Does CDIO Operate In?

The biotechnology industry is witnessing rapid advancements, particularly in diagnostics, driven by technological innovations and a growing emphasis on personalized medicine. The global cardiovascular diagnostics market is projected to grow significantly, fueled by increasing prevalence of cardiovascular diseases and the demand for early detection tools. Cardio Diagnostics Holdings, Inc. operates within this dynamic landscape, aiming to differentiate itself through its unique epigenetic approach. Competition is intense, with established players dominating the market, yet the increasing focus on preventative care presents opportunities for innovative solutions like those offered by Cardio Diagnostics.

Who Are CDIO's Key Customers?

• Healthcare providers seeking advanced diagnostic tools.
• Patients at risk of cardiovascular diseases.
• Research institutions focusing on cardiovascular health.
• Pharmaceutical companies looking for diagnostic solutions for clinical trials.

Over the past six months, Cardio Diagnostics Holdings, Inc. insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 24K shares acquired (about $50K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Cardio Diagnostics Holdings, Inc.

Revenue for Cardio Diagnostics Holdings, Inc. came in at $5K during Q2 FY2026, a 100.0% improvement versus the preceding quarter. The company recorded a net loss of $1.5M, with diluted EPS of $-0.51. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CDIO averaged $-0.73 in diluted EPS.

CDIO Valuation & Market Position

With a $5.86M market cap, Cardio Diagnostics Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CDIO's quantitative score of 22/100 is below the peer average of 75/100.

Return on equity for Cardio Diagnostics Holdings, Inc. stands at -78.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -69.6%, showing how much profit it generates from its asset base. A current ratio of 15.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -106.9%, the inverse of the P/E and a quick read on earnings relative to price.

Cardio Diagnostics Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.20 places it in the distress zone, a signal of elevated financial risk.

Cardio Diagnostics Holdings, Inc. has beaten Wall Street's EPS estimate in 6 of its last 7 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 107.4% below estimates on average.

Company Profile

Cardio Diagnostics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Meeshanthini V. Dogan. CDIO has traded publicly since 2022.

CDIO Financials

CDIO Latest News

CDIO Analyst Consensus

CDIO MoonshotScore

What Investors Ask About Cardio Diagnostics Holdings, Inc. (CDIO) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources